Abstract 566P
Background
Promising clinical activity has been reported in the INSIGHT 2 (NCT03940703) study of tepotinib (TEP) + osimertinib (OSI) in patients with EGFR-mutant (m) NSCLC with MET amplification (METamp) progressing on first-line OSI, with an objective response rate (ORR) of 50.0% (95% CI: 39.7, 60.3) and median duration of response (mDOR) of 8.5 months (95% CI: 6.1, not estimable [ne]). In patients enrolled in Asia, ORR was 59.6% (95% CI: 45.1, 73.0) and mDOR was 7.3 months (95% CI: 4.7, ne). Given the high incidence of EGFRm NSCLC in Asia, we report comprehensive safety data for patients enrolled in Asia to inform patient care and management.
Methods
TEP 500 mg (450 mg active moiety) was administered in combination with OSI 80 mg QD until disease progression, intolerable toxicity, or withdrawal. To manage AEs, drugs could be dose reduced or discontinued as needed. AE severity was graded by NCI-CTCAE v5.0. Data cut-off: March 28, 2023.
Results
Of 128 patients receiving TEP+OSI, 76 (59.4%) were enrolled in Asia. Of patients in Asia, treatment-related AEs (TRAEs) of any grade occurred in 67 patients (88.2%), and Grade ≥3 TRAEs occurring in 26 patients (34.2%). The most common TRAEs were diarrhea in 34 patients (44.7%; all Grade 1 or 2) and peripheral edema in 30 patients (39.5%; including 3.9% Grade ≥3) (Table). TRAEs led to a dose reduction of TEP and/or OSI in 14 patients (18.4%). The most common TRAEs leading to dose reduction were peripheral edema and decreased appetite (n=3 each). TRAEs led to permanent discontinuation in six patients (7.9%), with pneumonitis being the most common TRAE leading to discontinuation (n=3). TRAEs that led to death occurred in three patients: one patient had platelet count decrease (disease progression), one patient had pneumonitis, and one patient had respiratory failure (COVID-19). Table: 566P
TRAEs in ≥10% of patients in Asia (N=76), n (%) | Any grade | Grade ≥3 |
Any | 67 (88.2) | 26 (34.2) |
Diarrhea | 34 (44.7) | 0 |
Peripheral edema | 30 (39.5) | 3 (3.9) |
Hypoalbuminemia | 19 (25.0) | 1 (1.3) |
Paronychia | 18 (23.7) | 0 |
Decreased appetite | 15 (19.7) | 4 (5.3) |
Nausea | 14 (18.4) | 0 |
ALT increase | 12 (15.8) | 2 (2.6) |
Anemia | 12 (15.8) | 2 (2.6) |
AST increase | 12 (15.8) | 0 |
Blood creatinine increase | 11 (14.5) | 0 |
Rash | 11 (14.5) | 0 |
Lipase increase | 11 (14.5) | 2 (2.6) |
Weight decrease | 9 (11.8) | 0 |
Hypocalcemia | 9 (11.8) | 0 |
Dermatitis acneiform | 9 (11.8) | 0 |
Vomiting | 8 (10.5) | 0 |
Amylase increase | 8 (10.5) | 0 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE, treatment-related adverse event.
Conclusions
TEP+OSI was generally well tolerated in patients in Asia, comparable to the overall population. Most AEs were considered manageable with TEP and/or OSI dose modifications.
Clinical trial identification
NCT03940703.
Editorial acknowledgement
Medical writing assistance (funded by Merck) was provided by Vivian Anastasiou, PhD on behalf of Syneos Health, London, UK.
Legal entity responsible for the study
Merck Healthcare KGaA, Darmstadt, Germany.
Funding
Merck.
Disclosure
C.K. Liam: Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim ; Financial Interests, Personal, Other, Honoraria and fees for lectures and advisory board meetings: AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, Roche, Zuelig Pharma, Bristol Myer Squibbb, Merck, Janssen. T.M. Kim: Financial Interests, Personal, Advisory Role: AstraZeneca, Boryung, Hanmi, IMBDx.Inc, Janssen, Novartis, Takeda, Sanofi, Regeneron, Roche/Genentech, Samsung Bioepis. P. Voon: Financial Interests, Personal, Advisory Role: AstraZeneca, Ipsen, MSD, Novartis, Pfizer; Financial Interests, Personal, Research Funding: AstraZeneca, Novartis, Boehringer Ingelheim, Janssen-Cilag, Johnson & Johnson, Viracta Therapeutics Inc, Roche, Merck, MSD. L.M. Tho: Financial Interests, Personal, Advisory Board, Advisory Board & Speaker honoraria: Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Merck. H. Hayashi: Financial Interests, Personal, Other, Honoraria: Ono Pharmaceutical, Bristol Myers Squibb Japan, Lilly, Boehringer Ingelheim, Chugai Pharma, Pfizer, MSD, Novartis, Merck, Amgen, Daiichi Sankyo/ UCB Japan, Guardant Health, Takeda; Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo/UCB Japan, Janssen; Financial Interests, Personal, Research Funding: Ono Pharmaceutical, Boehringer Ingelheim, AstraZeneca, AbbVie, AC Medical, Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Lilly Japan, EPS Associates Co., Ltd., GSK, Japan Clinical Research Operations, Kyowa Hakko Kirin, Merck, Novartis, Otsuka, PAREXEL, Pfizer, PPD-SNBL, Quintiles Inc., Taiho Pharmaceutical, Takeda, Yakult Honsha, Chugai Pharma, Sysmex; Financial Interests, Personal, Other, Patents, Royalties, other intellectual Property: Sysmex. D.S.W. Tan: Financial Interests, Personal, Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 Therapeutics; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, Roche; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, Pfizer; Financial Interests, Personal, Research Funding: Novartis, GSK, AstraZeneca. P. Danchaivijitr: Financial Interests, Personal, Advisory Role: AstraZeneca, Roche, MSD; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: MSD; Financial Interests, Personal, Other, Honoraria: MSD, AstraZeneca, Roche; Financial Interests, Personal, Research Funding: Research University Network. J.C. Yang: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Daiichi Sankyo, MSD, Novartis, Roche/Genentech, Takeda Oncology, Yuhan Pharmaceuticals, Ono Pharmaceuticals, Pfizer, AstraZeneca ; Financial Interests, Personal, Research Funding: Eli Lily, JNJ, Puma Technology, Gilead, GSK, Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, MSD, Novartis, Roche/Genentech, Takeda Oncology, Yuhan Pharmaceuticals. X. Le: Financial Interests, Personal, Advisory Role: AstraZeneca, Lilly, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Spectrum Pharmaceuticals, Daiichi Sankyo/Lilly, Novartis, Hengrui Therapeutics, Janssen Oncology, Blueprint Medicines, Sensei Biotherapeutics, AbbVie, Arrivent; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Spectrum Pharmaceuticals, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA; Financial Interests, Personal, Research Funding: Lilly, Boehringer Ingelheim, Arrivent, Teligene. B. Ellers-Lenz, N. Karachaliou, V. Ghori, K. Berghoff: Financial Interests, Personal, Full or part-time Employment: Merck. Y. Wu: Financial Interests, Personal, Other, Institute grants and personal fees: AstraZeneca, Roche, Boehringer Ingelheim; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Eli Lilly, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract